News

InCarda Therapeutics Appoints Daniel G. Welch as Executive Chairman of Board of Directors

Former Chairman and CEO of InterMune Brings Extensive Development and Commercialization Experience to Support Continued Advancement of InRhythm™ for Treatment of Atrial Fibrillation SAN FRANCISCO, CA – April 3, 2019 – InCarda Therapeutics, Inc. (“InCarda”), a privately-held biopharmaceutical company developing first-of-their-kind inhaled therapies for cardiovascular diseases,...

New Patent Issuances Strengthen InCarda Therapeutics’ Intellectual Property Portfolio Covering Novel Inhaled Cardiovascular Therapies

U.S. Patent Broadly Expands Coverage for Inhaled Treatment of Cardiovascular Disease to Include all Class I – IV Antiarrhythmic Drugs Additional U.S. Patent Provides Coverage for Combination of Arrhythmia Electronic Monitoring with Treatment Initiation; Supports Vision of Empowering Patients to Rapidly Detect and Arrest Atrial Fibrillation...

InCarda Therapeutics Provides Corporate Update Highlighting Fundraising and Clinical Development Milestones

Oversubscribed $42 Million Series B Financing Provides Significant Runway to Support Continued Advancement of Innovative Inhaled Cardiovascular Therapy First Patients Dosed in Phase 2 Clinical Trial of First-of-its-Kind Inhaled Antiarrhythmic for Treatment of Paroxysmal Atrial Fibrillation San Francisco, CA – November 8, 2018 – InCarda Therapeutics, Inc....

InCarda Therapeutics Recruiting for Phase 2 Clinical Trial in PAF

InCarda Therapeutics is currently conducting a Phase 2 clinical trial (INSTANT) in patients with symptomatic paroxysmal atrial fibrillation (PAF). For more information, please refer to the clinicaltrials.gov registration link below. https://www.clinicaltrials.gov/ct2/show/NCT03539302?term=INSTANT&cond=Atrial+Fibrillation&rank=1...

InCarda Therapeutics Announces Positive Clinical Data Supporting Development of Inhaled Flecainide for the Treatment of Symptomatic Acute Events of Paroxysmal Atrial Fibrillation (PAF)

Flecainide administered via oral inhalation is well tolerated and elicits ECG changes suggestive of rapid drug delivery to heart Brisbane, California, June 7, 2017 – InCarda Therapeutics, Inc. (InCarda), a privately held biopharmaceutical company developing therapies for acute cardiovascular conditions via the inhalation route, today...

InCarda Therapeutics Elects Dr. Norbert Bischofberger to Board of Directors

San Francisco, California, June 7, 2016 – InCarda Therapeutics, Inc. (InCarda), a privately-held biopharmaceutical company focused on the development of therapies for cardiovascular conditions via the inhalation route, today announced the election of Norbert Bischofberger, Ph.D., to the company’s board of directors. Dr. Bischofberger has...